Brief: Ose Immunotherapeutics, Boehringer Ingelheim To Present Phase 1 Results With Inhibitor BI 765063

Ose Immunotherapeutics SA

13/09/2021 06:41

Sept 13 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * BOEHRINGER INGELHEIM AND OSE IMMUNOTHERAPEUTICS TO PRESENT
PHASE
1 RESULTS WITH FIRST-IN-CLASS SIRPΑ INHIBITOR BI 765063 IN
ADVANCED SOLID TUMORS AT ESMO 2021
    * PHASE 1 CLINICAL TRIAL AIMS TO EVALUATE SAFETY AND
EFFICACY OF
BI 765063 AS MONOTHERAPY AND IN COMBINATION WITH EZABENLIMAB (BI
754091; ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED SOLID TUMOURS
    * PHASE 1 CLINICAL STUDY OF BI 765063 IS BEING CONDUCTED BY
OSE
IMMUNOTHERAPEUTICS AS PART OF A COLLABORATION AND LICENSE
AGREEMENT UNDER WHICH BOEHRINGER INGELHEIM OBTAINED EXCLUSIVE
RIGHTS TO PRODUCT

Source text for Eikon:  ID:nBw61PSXha 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))